Mounjaro and Saxenda show how fast this drug class evolved: Saxenda is the daily liraglutide averaging about 8% weight loss; Mounjaro is the weekly dual-target tirzepatide pushing 22.5%. Both slow the stomach and both need the same food framework — the stakes just scale with the result.
| A | B | |
|---|---|---|
| Active ingredient | Liraglutide | Tirzepatide |
| Dosing | Daily | Weekly |
| Average weight loss | ~8% (SCALE) | Up to 22.5% (SURMOUNT-1) |
| Appetite effect | Milder, wears daily | Stronger, longer |
| Food rules | Same framework | Same framework, stricter |
The same judgment framework runs across this site — protein, fiber and how heavy a food sits on a slow stomach.
| Easy on both | Risky on both |
|---|---|
|
|
Cost, coverage, or tolerability. Its lighter effect can be enough for modest weight loss with fewer side effects — but the weight-loss ceiling is much lower.
Same framework. The practical difference is that Saxenda's effect fades daily, so keeping protein spread through the day matters more.
That is a provider conversation — doses and titration differ. The food habits you built on Saxenda carry over unchanged.
This comparison presents published trial data (STEP, SURMOUNT, SCALE, OASIS 4) and FDA label information for reference. It is not medical advice and does not recommend any medication. Prescription decisions belong to you and your healthcare provider.